Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 206-076-3 | CAS number: 299-29-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Via study data and read across Iron Gluconate is not classified as toxic
Justification for using read across for the actute toxicity via the dermal route is attached.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study without detailed documentation
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- No guideline available
- GLP compliance:
- not specified
- Remarks:
- GLP compliance of the report used to produce results not given in the publication
- Test type:
- other: no guideline available
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Blue Spruce Farms
- Weight at study initiation: 200-250 g
- Fasting period before study: 12 hours
- Water (e.g. ad libitum): Yes - Route of administration:
- oral: gavage
- Vehicle:
- other: Tris buffer
- Details on oral exposure:
- VEHICLE
- Amount of vehicle (if gavage): 1-3 ml - Control animals:
- not specified
- Details on study design:
- There are no details on the study design
- Statistics:
- Weil method
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- >= 2 237 mg/kg bw
- Based on:
- not specified
- Mortality:
- No data
- Clinical signs:
- other: Diarrhea seen at sub-lethal and lethal doses.
- Gross pathology:
- At doses higher or equal to the LD50 - stomach and small intestine were dilated and filled with dark fluid and occasionally blood. Stomach and small intestine mucosa were covered with grey-green granular material. Ceacum and large intestine containied black liquid faeces.
At sub-lethal doses - occasional dilation of upper gastrointestinal tract with fluid. Small hamorrhages were seen in stomach or small intestine. Black liquid faeces was reported. - Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- LD50 (rat) is 2237 mg/kg
Iron Gluconate is not classified as hazardous - Executive summary:
Iron Gluconate is not classified as hazardous
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 237 mg/kg bw
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- other:
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
- Quality of whole database:
- The test is waived as per column 2 in Annex VIII
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- 2009
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study with acceptable restrictions
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- yes
- Remarks:
- housing of the animals was in individual cages, drinking water analysis was performed in September instead of August, dosing of males occurred one week prior to the completion of the female study
- Principles of method if other than guideline:
- housing of the animals was in individual cages, drinking water analysis was performed in September instead of August, dosing of males occurred
one week prior to the completion of the female study - GLP compliance:
- yes
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories France, Domaine des Oncins, 69592 L'Arbresle Cedex, France.
- Weight at study initiation: 223.9 to 243.6 g for females, and 257.6 to 296.4 g for males
- Fasting period before study: None
- Housing: Individually caged in standard cages with sawdust bedding
- Diet (e.g. ad libitum): RM1 (E)-SQC/DIETEX feed ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period:Minimum 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24
- Humidity (%): 45-65
- Air changes (per hr): 10
- Photoperiod (hrs dark / hrs light): 12 hrs dark/ 12 hrs light - Type of coverage:
- semiocclusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- TEST SITE
- Area of exposure: Dorsal area of the rat
- % coverage: at least 10%
- Type of wrap if used: Piece of absorbant gauze which was protected by a pad and covered with an adhesive tape. Held in place for 24 hours.
REMOVAL OF TEST SUBSTANCE
- Washing (if done): Not done
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 2000 mg/kg body weight
- Concentration (if solution): undiluted
- Constant volume or concentration used: yes - Duration of exposure:
- 24 hours
- Doses:
- 2000 mg/kg body weight
- No. of animals per sex per dose:
- 5 animals per sex
- Control animals:
- not required
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Animals were examined clinically before the first treatment, twice on the day of treatment, and thereafter, daily. Animals were weighed on day 1, 7, 14 and 15
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight, organ weights, histopathology, other: Skin lesion evaluation was done daily, and full clinical examinations were done on days 2, 7, and 14. At necropsy their organs were examined macroscopically.
As the test item was expected to be non-toxic by the dermal route, a single group of 5 females was dosed at the maximum limit dose of 2000 mg/kg body weight followed by a group of 5 males dosed at the same dose level to establish that animals of this sex are not markedly more sensitive to Gluconic Acid.
Scoring system of skin lesions
Erythema and Eschar formation
No erythema 0
Very slight erythema (barely perceptible) 1
Well-defined erythema 2
Moderate to marked erythema 3
Severe erythema (beet redness) to slight eschar formation preventing the grading of the erythema 4
Formation of oedema
No oedema 0
Very slight oedema (barely perceptible) 1
Slight oedema (edges of area well-defined by definited raising) 2
Moderate oedema (raised approximately 1 mm) 3
Severe oedema (raised more than 1 mm) extending beyond the area of exposure) 4 - Statistics:
- Not reported; however, not required for acute toxicity.
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Mortality:
- No mortality occurred during the study in male and female Sprague-Dawley rats.
- Clinical signs:
- other: No clinical signs were observed during the course of the study.
- Gross pathology:
- No organ or tissue gross findings were seen at necropsy.
- Other findings:
- No dermal reactions were observed during the course of the study.
- Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: other: CLP (EC 1278/2008)
- Conclusions:
- D-Gluconic Acid is not toxic
- Executive summary:
D-Gluconic Acid is not classified as toxic
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
Additional information
Iron Gluconate is classified as non-hazardous for this end point
Justification for selection of acute toxicity – inhalation endpoint
The test is waived as per column 2 in Annex VIII
Justification for selection of acute toxicity – dermal endpoint
There are no acute dermal toxicity studies on ferrous gluconate. Results of a study conducted with a structurally similar compound, D-gluconic acid, are reported and used for read across. From this read across ferrous gluconate is not classified as toxic.
Via read across Iron Gluconate is classified as non-hazardous for this end point
Justification for classification or non-classification
Via study data (acute toxicity: oral) and read across (acute toxicity: dermal) Iron Gluconate is not classified as toxic.
Iron Gluconate can be read across to D-Gluconic acid due to the comparable structures, similar minimal levels of dermal absorption and similar phys/chem properties relevant for determining dermal toxicity.
The pKa of most gluconic acid salts, including iron gluconate is 3.7 (OECD SIDS 2004). Henderson-Hasselbad modelling predicts that at the skin pH of 5, the majority of the iron gluconate will be present as the dissociated Fe++ ion and gluconate and, as a result, will be poorly absorbed (Wikipedia 2014). The read across material, d-gluconic acid has a similar pKa (3.86) and is also poorly absorbed for the same reason. However, once absorbed the gluconate will undergo the same fate and make the same contributions to systemic effects regardless of whether it comes from the iron gluconate or from the read across material, the gluconic acid.
The absorbed iron portion of the molecule will likewise be minimal but that which is absorbed will have similar distribution, metabolism and systemic effects as dietary sources of iron. Mammalian systems have numerous homeostatic mechanism for maintaining appropriate systemic iron levels (Andrews and Schmidt 2007). The minor amounts absorbed dermally from iron gluconate are not likely to overwhelm those mechanisms.
Full justification for using read across for the actute toxicity via the dermal route is attached.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.